Current medical news and unique business news for anyone that cares about the healthcare industry.
A better way to fund medical devices? Call it “early in early out.” Mach Ventures’ approach to investing in medical devices: sell after the company proves the device can work or after FDA approval. “No infrastructure, no management, and no duplication that the acquirer needs to get rid of. It’s more honest—and a lot more fun,” writes John Lonergan, Mach’s managing member. Lonergan says the current venture capital approach fails medical devices (and biotech, for that matter).
Healthcare smartphone applications. Revenues from smartphone medical apps used by healthcare professionals grew to an estimated $84.1 million in 2010.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Victories for death panelists. End-of-life planning, inserted into Medicare reimbursement regulations, will now be removed.
Health CEOs special healthcare benefit. Nine of 12 CEOs of major healthcare trade groups were paid $1 million in 2009. “There is no one formula [for] association compensation,” said Nels Olson, managing director of at head hunting firm Korn/Ferry. “But one that is relevant here is advocacy, given the health care debate in Washington.” Meanwhile, only one in 10 top health lobbyists broke $1 million.
Venture capital zombies… include eight healthcare investment funds: HIG Ventures, HealthCare Ventures, Hopewell Ventures, Kodiak Venture Partners, MedVenture Associates, Mission Ventures, Prospect Ventures and Sanderling Venture Partners.
Accenture: The healthcare consultant. Watch Accenture’s Group Chief Executive Stephen Roedler discuss the company’s plans to be known as a healthcare company.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Dealflow and more. Dry eye drugmaker Eyegate Pharmaceuticals added $5.9 to a round now totaling $28.5 million; DBV Technologies, which is making a peanut allergy patch, raised $25.5 million; osteoporosis medical device company Graftys raised $5.3 million for a U.S. expansion; and obesity devicemaker Satiety has raised $68 million but wants to sell.
